Health Decisions (Durham, NC) has a new company in its Agile Clinical Network, a community of research partners with the goal of higher efficiency standards in complex global studies.KLIXAR, an Argentinian CRO, has received certification after completing "rigorous" training in Agile Clinical development techniques.
“Our alliance with Health Decisions will enable us to broaden our customer base while providing unparalleled efficiency and transparency to pharmaceutical companies in Latin America,” said said Enrique Gaubeca, managing director at KLIXAR, in a company press release.
As part of the newly launched Network, KLIXAR will have access to Health Decisions’ data management systems, biostatistics expertise, medical writers, advanced data collection tools, and real-time reporting capabilities.
"We look forward to working with KLIXAR and all our Agile Clinical Network partners to raise the standards of efficiency for global clinical trials," said Rick Farris, COO at Health Decisions. "By producing rapid, accurate results for our sponsors regardless of geographic boundaries, we hope to shape the future of drug development..."
For more information about the Network, click here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Long-Term Analysis Shows Tafinlar Plus Mekinist Reduces Mortality Risk in Stage III Melanoma
November 11th 2024Phase III COMBI-AD trial final analysis shows that 12 months of adjuvant therapy with Tafinlar (dabrafenib) and Mekinist (trametinib) in patients with resected stage III melanoma significantly improved relapse-free survival and distant metastasis-free survival compared to placebo.